Dates and location
November 25, 2021
13:00h - 14:00h
15:00h - 21:00h
Lecture hall 4, location AMC Amsterdam UMC
link to meeting
Attending the symposium is free of charge, however registration is for everybody.
Registration is open: Register now!!!
13:00 - 14:00h Meet-the-expert Lunch
Before the symposium, there will be a Meet-the-Expert Lunch for PhD candidates and (junior) post docs with Stefano Romeo and Patrick Rensen. This is a unique opportunity to meet with these experts in the field and personally ask them questions about their experiences in medical research and career development.
15:00 - 15:30h Walk In
15:30 - 15:40h Introduction
15:40 - 16:05h Paul Yen (Duke University Singapore, via Zoom)
16:15 - 16:40h Stefano Romeo (Gothenburg University)
16:50 - 17:15h Stan van de Graaf (Amsterdam UMC)
17:15 - 17:45h Coffee break
17:45 - 17:55h Short talk 1: Milena Schönke (LUMC)
18:00 - 18:10h Short talk 2: Willemien van Zwol (UMCG, via Zoom)
18:15 - 18:25h Short talk 3: Dicky Struik (UMCG)
18:30 - 18:40h Short talk 4: Dyonne Vos (UMCG)
18:45 - 19:45h Dinner
19:45 - 20:10h Patrick Rensen (LUMC)
20:20 - 20:45h Vlad Ratziu (Sorbonne University)
20:55 - 21:10h Closing
Prof. Paul Yen
Duke-NUS Medical School and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program in Singapore
"Novel therapies for NASH with natural compounds"
Dr. Yen is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He obtained his M.D. from Johns Hopkins, completed residency in internal medicine at University of Chicago, and fellowship training in endocrinology at NIH. He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. He is the recipient of the 2020 AOTA Nagataki Fujifilm Prize for his contributions to clinical and basic thyroid research. His research interests include endocrine regulation of transcription, autophagy, and lipid metabolism in normal and disease states such as non-alcoholic fatty liver disease, GSD1a, Citrin deficiency, diabetes and obesity.
Prof. Stefano Romeo
Professor in Molecular and Clinical Medicine at the Sahlgrenska Academy in the Institute of Medicine at Gothenburg University and Senior Consultant in Endocrinology and metabolism at Sahlgrenska University Hospital in Gothenburg Sweden.
"Novel genetic determinants of fatty liver disease"
Stefano Romeo is Professor in Molecular and Clinical Medicine at the Sahlgrenska Academy in the Institute of Medicine at Gothenburg University and Senior Consultant in Endocrinology and metabolism at Sahlgrenska University Hospital in Gothenburg.
Dr. Romeo’s main research focus is the role of genetic variants in modulating metabolic liver disease and serum lipid levels. His research field ranges from genetic association studies in large cohorts to understanding molecular mechanisms underlying the genetic associations. His main clinical commitment is to drive the Lipid Clinic.
Prof. Stan van de Graaf
Professor of Experimental Hepatology and Metabolism at the Amsterdam UMC and co-director of the research institute Amsterdam Gastroenterology, Endocrinology, Metabolism (AGEM) at UMC, Amsterdam The Netherlands.
"Hepatic bile acid uptake as a target to halt the fatty liver epidemic"
Stan van de Graaf recently received a VICI grant to continue and broaden his research line on NAFLD. His group recently identified the hepatic bile acid uptake transporter NTCP (Na/taurocholate Cotransporting Polypeptide) as a safe and efficient target to enhance and prolong bile acid signalling using the body’s own bile acid pool. NTCP inhibition reduces the amount of hepatic fat in high-calorie feeding conditions and independently also leads to dampening of inflammation, and therefore could be a promising new target to treat NAFLD.
Prof. Patrick Rensen
Professor of Endocrinology at the Leiden University Medical Center Leiden (LUMC) in Leiden, The Netherlands.
"Hormones to comBAT NAFLD"
Prof. Patrick Rensen’s lab mainly focuses on the role of energy metabolism in cardiometabolic diseases including obesity, NASH and atherosclerotic cardiovascular disease. To this end, intervention studies in metabolically vulnerable populations are combined with mechanistic studies in APOE*3-Leiden.CETP mice, an in-house unique model for human cardiometabolic diseases.
Prof. Vlad Ratziu
Professor of Hepatology at Sorbonne University in Paris, France
"Latest developments in NASH therapies"
Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia.
Organized by the AGEM research institute in collaboration with the Dutch NAFLD-NL consortium.
Anne-Marieke van Dijk
Anne Linde Mak
Linda van den Noord
For questions contact AGEM (email@example.com)
Prof. Saskia van Mil, UMC
Dr. Maarten Tushuizen, LUMC